Homepage Archives - Geneseeq Technology Inc. | A Precision Oncology Company

March 9, 2023

Geneseeq and Collaborators Initiate MOTION Study to Evaluate the Performance of Minimal Residual Disease Test SHIELDING™ in Early-stage Lung Cancer

January 24, 2023

Geneseeq receives CE Marks for MRD and MCED tests.

November 3, 2022

Geneseeq study evaluates the clinical value of cell-free DNA 5’-end motif profile in the prediction of pathological complete response for LARC patients after neoadjuvant chemoradiotherapy

October 18, 2022

Geneseeq study highlights ctDNA monitoring clinical value in colorectal cancer patients resistant to BRAF/EGFR-targeted therapy

October 12, 2022

Interesting findings on ctDNA-based MRD detection in patients with resectable non-small cell lung cancer by Geneseeq

September 7, 2022

Geneseeq to present five posters at European Society for Medical Oncology 2022

August 3, 2022

GENESEEQ AND COLLABORATORS SHARE NEW FINDINGS AT WORLD CONFERENCE ON LUNG CANCER 2022

July 19, 2022

Geneseeq, Brazilian Hospital Partner on Co-establishment of In-house NGS Lab

July 5, 2022

Geneseeq and collaborators publish new findings from DECIPHER series, exploring single cfDNA feature-based machine learning model for lung cancer early detection

June 13, 2022

Geneseeq Multicancer Early Detection Study Yields Promising Results